Wyeth Ltd.- (Amalgamated) Stock Analysis

BSE: 500095 | NSE: WYETH | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Wyeth

Overall Rating

2. Valuation

Undervalued
P/E P/S EV/EBITDA

3. Price Trend

FAQ's

1. Is Wyeth Ltd.- (Amalgamated) a good quality company?

Data is not available for this company.

2. Is Wyeth Ltd.- (Amalgamated) undervalued or overvalued?

No data found

3. Is Wyeth Ltd.- (Amalgamated) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Wyeth Ltd.- (Amalgamated) is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Wyeth:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
Mar'05Mar'06Mar'07Mar'08Mar'09Nov'09Mar'11Mar'12Mar'13Mar'14TTM
ROCE % 16%24.5%35.8%31.4%38.4%21.2%49.8%33.7%25.4%23.6%-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 256287288331383430481589678679735
YoY Gr. Rt. %-12.4%0.3%15%15.5%12.3%12%22.4%15.3%0.2%-
Adj EPS 17.626.539.835.945.138.754.664.458.743.648.1
YoY Gr. Rt. %-50.3%50.4%-10%25.8%-14.3%41.1%18%-8.9%-25.8%-
BVPS (₹) 106.7108113113.7119.6183.2127212.1249.5118.5145.8
Adj Net Profit 40.160.290.581.510287.812414613399109
Cash Flow from Ops. 29.460.57985.860.286.611376.492.3119-
Debt/CF from Ops. 0.1000000000-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 11.5%12.2%12.2%0.2%
Adj EPS 10.6%-0.7%-7.2%-25.8%
BVPS 1.2-0.2-2.3-52.5
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'05Mar'06Mar'07Mar'08Mar'09Nov'09Mar'11Mar'12Mar'13Mar'14TTM
Return on Equity % 16.124.736.131.638.721.349.933.825.423.736.4
Op. Profit Mgn % 524.434.731.934.527.835.231.524.517.419.5
Net Profit Mgn % 15.72131.424.626.820.525.824.919.714.614.9
Debt to Equity 00000000000
Working Cap Days 17013712911512620097134148161211
Cash Conv. Cycle 31-22210-25-41114-44110

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Wyeth Ltd.- (Amalgamated)

Standalone Consolidated
TTM EPS (₹) 48.1 29.8
TTM Sales (₹ Cr.) 735 287
BVPS (₹.) 145.8 0
Reserves (₹ Cr.) 309 223
P/BV 9.15 0.00
PE 27.72 44.78
From the Market
52 Week Low / High (₹) 1330.25 / 1395.90
All Time Low / High (₹) 171.00 / 1409.00
Market Cap (₹ Cr.) 3,032
Equity (₹ Cr.) 22.7
Face Value (₹) 10
Industry PE 39.1

Management X-Ray of Wyeth :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Wyeth Ltd.- (Amalgamated)

Wyeth Limited (Wyeth) the Indian subsidiary of US-based Pharma Company Wyeth and now a Pfizer group company, is a global leader in pharmaceutical, consumer healthcare and animal health products. It was established in 1947 as a private limited company under the name Lederle Laboratories (India) Ltd. In 1962, the name was changed to Cyanamid India Ltd. The company became a public enterprise in 1965. In 1998, three companies - Wyeth Laboratories, John Wyeth India and Wyeth India (Pvt) Ltd -- were transferred to the company and its name was changed to Wyeth Lederle Ltd. In 2003, Geoffrey Manners & Co Ltd was merged and the name of the company was changed to Wyeth Ltd.

The pharmaceuticals business of the company comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products. It has a manufacturing facility in Goa. The company was a pioneer, introducing several new therapies such as hormone therapy, in India. In the field of vaccines, the company introduced vaccines against HIB and invasive pneumococcal disease.

It has launched several products that are known internationally such as Enbrel-for treatment for rheumatoid arthritis, Rapamune- an immuno suppressant for prevention of rejection after renal transplant and Prevenar- a pneumococcal conjugate vaccine. The company launched the world's first glycilcycline antibiotic, Tygacil. Wyeth manufactures drugs in areas of antibiotics, steroids, vaccines, cardiovascular system, vitamins and hematinics, central nervous system and immunology.

On November 23, 2013, the Board of Directors of Pfizer India and Wyeth India at their meetings approved a proposal to merge Wyeth India with Pfizer India. The appointed date for the merger was April 1, 2013, the swap ratio, post interim dividend for the merger was 7 shares of Pfizer India (face value of Rs 10 each), for every 10 shares of Wyeth India (face value of Rs 10 each)

Milestones

Acquisition of Wyeth, USA by Pfizer Inc

In 2009, Wyeth of USA merged with Wagner Acquisition Corp, a direct, wholly-owned subsidiary of Pfizer Inc. As a result of the merger, Pfizer Inc is now the parent company of Wyeth and hence the ultimate parent of the Indian company. Pfizer acquired Wyeth for $68 billion in order to diversify its product portfolio, which includes Wyeth's major biotech drugs and vaccines. In India, Pfizer Ltd and Wyeth Ltd continue as two separate entities.

FY09: Strong performance from key products; new product launches

In the period ended November 30, 2009 Wyeth continued to maintain its leadership position in oral contraceptives, hormone therapy and folic acid markets. Two key products saw strong growth -- Enbrel, a breakthrough treatment for rheumatoid arthritis and psoriasis, achieved growth of 38%, while Prevenar, a vaccine for invasive pneumococcal disease, achieved growth of 75%. An applicator “Anne French roll-on” with additional features attracted new consumers. The newly launched Anacin Multi-Pain has broadened the brand’s relevance for consumers by targeting more usage occasions than before.

FY09: Strong performance from key products; new product launches

Wyeth exports pharmaceutical and healthcare products predominantly to the USA, Europe and Japan. As of November 2009, exports accounted for 30% of its total turnover.

Read More Read Less